Genetic sequencing firm Illumina, Inc. has agreed to pay $325m to rival BGI, putting an end to multiple intellectual property suits that had been pending between the two companies. The resolution was announced in a 14 July filing with the US Securities and Exchange Commission.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?